Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04028167 · ClinicalTrials.gov registry record · Phase 2
Induction FLOT With CROSS CRT for Esophageal Cancer
A Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT04028167 is a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 40 participants, below the 87-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (54% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT04028167, a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin and paclitaxel, as neoadjuvant therapy prior to definitive surgical resection for patients with adenocarcinoma of the esophagus or gastroesophageal junction
Conditions Studied
Interventions
- DRUG Sequential FLOT followed by chemoradiation
Study Locations (7)
Colorado
- University of Colorado Hospital - Aurora
- UCHealth Southern Colorado - Memorial Hospital Central - Colorado Springs
- UCHealth Southern Colorado - Memorial Hospital North - Colorado Springs
- UCHealth Northern Colorado - Poudre Valley Hospital - Fort Collins
- UCHealth Northern Colorado - Harmony Campus - Fort Collins
- UCHealth Northern Colorado - Greeley Hospital - Greeley
- UCHealth Northern Colorado Medical Center of the Rockies - Loveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2027-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04028167
The ClinicalTrials.gov registry entry for NCT04028167 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (54% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenocarcinoma of the Gastroesophageal Junction appearing as the primary indexed condition, and to 1 intervention - of which Sequential FLOT followed by chemoradiation is the first listed.
NCT04028167 reports 7 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04028167 about?
NCT04028167 is a clinical study titled "Induction FLOT With CROSS CRT for Esophageal Cancer". This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin and paclitaxel, as neoadjuvant therapy prior to definitive surgical resec...
What is the current status of trial NCT04028167?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-04-08. Estimated completion is 2027-04-19.
What conditions does trial NCT04028167 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma Esophagus.
What interventions are being tested in trial NCT04028167?
The interventions under investigation include: Sequential FLOT followed by chemoradiation (DRUG).
Who is sponsoring clinical trial NCT04028167?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04028167 being conducted?
This trial has 7 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Gastroesophageal Junction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
COMPLETED · Phase 2
-
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
COMPLETED · Phase 2
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
Explore more on PlainTrial
Adenocarcinoma of the Gastroesophageal Junction
All registered trials for this condition
Adenocarcinoma Esophagus
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.